589 related articles for article (PubMed ID: 9429222)
1. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
2. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
3. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
4. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
Wakamatsu K; Ito S; Horikoshi T
Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
[TBL] [Abstract][Full Text] [Related]
5. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Oncology; 1999; 56(4):338-44. PubMed ID: 10343200
[TBL] [Abstract][Full Text] [Related]
6. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
7. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
8. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
Schultz ES; Diepgen TL; Von Den Driesch P
Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
[TBL] [Abstract][Full Text] [Related]
10. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma.
von Schoultz E; Hansson LO; Djureen E; Hansson J; Kärnell R; Nilsson B; Stigbrand T; Ringborg U
Melanoma Res; 1996 Apr; 6(2):133-7. PubMed ID: 8791271
[TBL] [Abstract][Full Text] [Related]
12. Some indolic compounds as markers of the melanocyte activity.
Hansson C
Acta Derm Venereol Suppl (Stockh); 1988; 138():1-60. PubMed ID: 3176811
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy.
Hauschild A; Engel G; Brenner W; Gläser R; Mönig H; Henze E; Christophers E
Br J Dermatol; 1999 Jun; 140(6):1065-71. PubMed ID: 10354072
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
18. The stability of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in human urine.
Kågedal B; Lenner L; Arstrand K; Hansson C
Pigment Cell Res; 1992; Suppl 2():304-7. PubMed ID: 1409435
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.
Hauschild A; Michaelsen J; Brenner W; Rudolph P; Gläser R; Henze E; Christophers E
Melanoma Res; 1999 Apr; 9(2):155-61. PubMed ID: 10380938
[TBL] [Abstract][Full Text] [Related]
20. Melanin-related metabolites in urine of B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1988; 68(5):385-9. PubMed ID: 2461020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
